What Researchers Did
Researchers investigated whether adding low-dose platinum chemotherapy improved the effectiveness of interstitial hyperthermia and iridium-192 radiation for treating locally advanced head and neck malignancies.
What They Found
The study found similar freedom from relapse rates (70% for chemotherapy vs. 63% for no-chemotherapy) and overall survival rates (28% vs. 31%) between groups, with no statistically significant difference. Complete response rates were 93% for the chemotherapy group and 86% for the no-chemotherapy group, and complication rates were comparable.
What This Means for Canadian Patients
For Canadian patients with locally advanced head and neck cancers, this study suggests that adding low-dose platinum chemotherapy to interstitial hyperthermia and iridium-192 treatment may not significantly improve relapse-free survival or overall survival. Patients should discuss all treatment options and their potential benefits with their oncology team.
Canadian Relevance
This study covers locally advanced head and neck malignancies, a recognized condition. Hyperbaric oxygen therapy (HBOT) was used to manage complications in some patients, which is a Health Canada-recognized indication for radiation tissue damage.
Study Limitations
A limitation of this study is its relatively small sample size (36 patients) and short median follow-up period (8 months), which may limit the generalizability and long-term assessment of outcomes.